CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
01 мая 2021 года
20:34
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
Текст новости:
Title: CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
Author, co-author: Onesti, Concetta E.; Jerusalem, Guy
Abstract: Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved.Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbociclib and ribociclib showed high rates of hematological toxicity, primarily neutropenia, and were associated with a low rate of severe infections. Abemaciclib was associated with a high rate of gastrointestinal toxicities, primarily diarrhea, of grade 1-2 in most cases. Ribociclib was associated with a high rate of hepatic, and respiratory toxicity and with QTc prolongation. The toxicity rate of ribociclib was higher in metastatic patients than non-metastatic patients, with approximately 33% more grade 3-4 toxicities and 21% more grade 3-4 neutropenic events. A 5% higher risk of diarrhea was observed in postmenopausal patients. Pre-treated patients did not show a higher toxicity rate for palbociclib/ribociclib than previously untreated patients, while a 26% higher risk of any grade neutropenia and 6% higher risk of grade 3-4 diarrhea were observed with abemaciclib.Expert opinion: Considering the similar efficacies and indications of palbociclib, ribociclib, and abemaciclib, the evaluation of their toxicity profiles may facilitate treatment choice.

Связанные объекты: #A (найти в новостях).

Текст со страницы (автоматическое получение):
Title :
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
Language :
Publication date :
Abstract :
[en] Introduction: CDK4/6 inhibitor approval for hormone-responsive breast tumors has significantly changed therapeutic algorithms, with three drugs currently approved.Areas covered: Here, we analyze the toxicity profiles of palbociclib, ribociclib, and abemaciclib through a systematic review and meta-analysis. Palbociclib and ribociclib showed high rates of hematological toxicity, primarily neutropenia, and were associated with a low rate of severe infections. Abemaciclib was associated with a high rate of gastrointestinal toxicities, primarily diarrhea, of grade 1-2 in most cases. Ribociclib was associated with a high rate of hepatic, and respiratory toxicity and with QTc prolongation. The toxicity rate of ribociclib was higher in metastatic patients than non-metastatic patients, with approximately 33% more grade 3-4 toxicities and 21% more grade 3-4 neutropenic events. A 5% higher risk of diarrhea was observed in postmenopausal patients. Pre-treated patients did not show a higher toxicity rate for palbociclib/ribociclib than previously untreated patients, while a 26% higher risk of any grade neutropenia and 6% higher risk of grade 3-4 diarrhea were observed with abemaciclib.Expert opinion: Considering the similar efficacies and indications of palbociclib, ribociclib, and abemaciclib, the evaluation of their toxicity profiles may facilitate treatment choice.
Permalink :
Автоматическая система мониторинга и отбора информации
Источник
Другие материалы рубрики
  01 мая 2021 года
16:33
A spontaneous arterial thrombosis in a preterm infant
  01 мая 2021 года
05:16
Un cas de myasthenie diagnostiquee trouble de conversion
ТОП-10 статей
1. Авиакомпания Conviasa открыла полеты из Международного аэропорта Внуково в Каракас
2. NI поделился сравнением российского истребителя Миг-29 с F/A-18 ВМС США
3. 85 лет со дня рождения Станислава Даниловича Куликова
4. «Деньги на ветер»: В США комментируют решение ВМС вывести из эксплуатации два литоральных корабля за 10-12 лет до истечения сроков
5. Повышение помехоустойчивости навигационной аппаратуры потребителя ГНСС на основе алгоритмов многосигнального приема
6. Живущих в тайге старообрядцев привлекли к подготовке спецназа
7. Безопасность российских туристов в аэропортах Хургады и Шарм-эль-Шейха обеспечат силовики из Москвы
8. ЦАХАЛ наносит удары по десяткам целей в секторе Газа
9. НКА «Глонасс-М» №723 используется по целевому назначению
10. Eviation готовится к полету своего потрясающего роскошного электрического самолета Alice


Ресурсы